GlassScriptPhysician profile
Stephen G Rohn
NPI 1689604472
$9,224.44
in general payments reported to CMS, 2019-2025
33 companies · $889 in 2025
The $889 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,995 · 2020: $990 · 2021: $1,763 · 2022: $1,920 · 2023: $1,213 · 2024: $454 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,997.63 | 2019-2024 | Xarelto |
| Amgen INC. | $1,324.81 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,304.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $726.25 | 2019-2025 | Farxiga, Wainua |
| Pfizer INC. | $603.43 | 2019-2025 | |
| Boston Scientific Corporation | $559.48 | 2019-2025 | Watchman Access System, Bodyguardian, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $486.82 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $381.74 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.05 | 2019-2025 | Jardiance |
| Medtronic Vascular, INC. | $188.21 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $146.52 | 2021-2025 | Verquvo, Belsomra |
| E.R. Squibb & Sons, L.L.C. | $122.17 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $118.93 | 2021-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $101.49 | 2019-2025 | Opsumit, Uptravi |
| Irhythm Technologies, INC. | $85.89 | 2023-2024 | Zio Xt Patch, Zio Monitor |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $83.01 | 2019 | |
| Amarin Pharma, INC. | $74.77 | 2019 | |
| Atricure, INC. | $72.59 | 2023 | |
| Siemens Medical Solutions USA, INC. | $60.67 | 2022-2024 | Artis Icono Floor |
| Bayer Healthcare Pharmaceuticals INC. | $59.40 | 2021-2025 | |
| Scpharmaceuticals INC. | $57.42 | 2024-2025 | |
| Abbott Laboratories | $49.77 | 2022-2023 | Cardiomems |
| Portola Pharmaceuticals, LLC | $40.81 | 2019-2020 | |
| Vital Connect, INC | $40.06 | 2024 | Vitalpatch Rtm |
| Cardiva Medical, INC. | $39.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $38.45 | 2021-2022 | |
| Cardiovascular Systems INC. | $32.35 | 2019 | |
| Kestra Medical Technology Services, INC. | $24.58 | 2025 | Assure Wcd |
| United Therapeutics Corporation | $23.64 | 2019 | |
| Heartflow, INC. | $17.27 | 2025 | |
| Medtronic, INC. | $15.90 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $14.99 | 2023 | Inpefa |
| Gilead Sciences, INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Rohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.